Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Next Previous
X
Search
Trial Profile

Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Alum; AS04A; Hepatitis A vaccine inactivated
  • Indications Adenocarcinoma; Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Aug 2022 Planned End Date changed from 5 Jul 2022 to 31 Dec 2023.
    • 12 Aug 2022 Planned primary completion date changed from 5 Jul 2022 to 31 Dec 2023.
    • 13 Jun 2022 Results (n=8156) of an analysis of this long-term follow-up study from the randomised CVT Trial published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top